» Articles » PMID: 22927469

Clinical Features of Schwannomatosis: a Retrospective Analysis of 87 Patients

Overview
Journal Oncologist
Specialty Oncology
Date 2012 Aug 29
PMID 22927469
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Schwannomatosis is a recently recognized form of neurofibromatosis characterized by multiple noncutaneous schwannomas, a histologically benign nerve sheath tumor. As more cases are identified, the reported phenotype continues to expand and evolve. We describe the spectrum of clinical findings in a cohort of patients meeting established criteria for schwannomatosis.

Methods: We retrospectively reviewed the clinical records of patients seen at our institution from 1995-2011 who fulfilled either research or clinical criteria for schwannomatosis. Clinical, radiographic, and pathologic data were extracted with attention to age at onset, location of tumors, ophthalmologic evaluation, family history, and other stigmata of neurofibromatosis 1 (NF1) or NF2.

Results: Eighty-seven patients met the criteria for the study. The most common presentation was pain unassociated with a mass (46%). Seventy-seven of 87 (89%) patients had peripheral schwannomas, 49 of 66 (74%) had spinal schwannomas, seven of 77 (9%) had nonvestibular intracranial schwannomas, and four of 77 (5%) had intracranial meningiomas. Three patients were initially diagnosed with a malignant peripheral nerve sheath tumor; however, following pathologic review, the diagnoses were revised in all three cases. Chronic pain was the most common symptom (68%) and usually persisted despite aggressive surgical and medical management. Other common diagnoses included headaches, depression, and anxiety.

Conclusions: Peripheral and spinal schwannomas are common in schwannomatosis patients. Severe pain is difficult to treat in these patients and often associated with anxiety and depression. These findings support a proactive surveillance plan to identify tumors by magnetic resonance imaging scan in order to optimize surgical treatment and to treat associated pain, anxiety, and depression.

Citing Articles

Predicting high-risk clinical missense variants of SMARCB1 in rare neurogenetic disorder schwannomatosis (nerve tumor) through sequence, structure, and molecular dynamics analyses.

Patel M, Binsuwaidan R, Surti M, Alshammari N, Ibrahim A, Adnan M Neurogenetics. 2025; 26(1):31.

PMID: 39976804 DOI: 10.1007/s10048-025-00812-z.


Improvements in pain interference among geographically diverse adults with neurofibromatosis: Results from a fully powered randomized controlled trial.

Hooker J, Doorley J, Greenberg J, Bakhshaie J, Manglani H, Briskin E Neurooncol Pract. 2025; 12(1):58-67.

PMID: 39917761 PMC: 11798604. DOI: 10.1093/nop/npae084.


Optimal Delivery of Pain Management in Schwannomatosis: A Literature Review.

Hino U, Tamura R, Toda M Ther Clin Risk Manag. 2025; 21():61-68.

PMID: 39839825 PMC: 11748755. DOI: 10.2147/TCRM.S362794.


Classification of schwannomas and the new naming convention for "neurofibromatosis-2": Genetic updates and international consensus recommendation.

Rai P, Bathla G, Soni N, Desai A, Rao D, Vibhute P Neuroradiol J. 2025; 19714009251313510.

PMID: 39786185 PMC: 11719429. DOI: 10.1177/19714009251313510.


Specifics of spinal neuropathology in the molecular age.

Kresbach C, Hack K, Ricklefs F, Schuller U Neurooncol Adv. 2024; 6(Suppl 3):iii3-iii12.

PMID: 39430396 PMC: 11485660. DOI: 10.1093/noajnl/vdad127.


References
1.
Parry D, Eldridge R, Bouzas E, Pikus A, Patronas N . Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994; 52(4):450-61. DOI: 10.1002/ajmg.1320520411. View

2.
Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B . Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2009; 11(1):73-80. DOI: 10.1007/s10048-009-0204-2. View

3.
Maccollin M, Chiocca E, Evans D, Friedman J, Horvitz R, Jaramillo D . Diagnostic criteria for schwannomatosis. Neurology. 2005; 64(11):1838-45. DOI: 10.1212/01.WNL.0000163982.78900.AD. View

4.
Smith M, Kulkarni A, Rustad C, Bowers N, Wallace A, Holder S . Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A. 2011; 158A(1):215-9. DOI: 10.1002/ajmg.a.34376. View

5.
Swensen J, Keyser J, Coffin C, Biegel J, Viskochil D, Williams M . Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet. 2009; 46(1):68-72. PMC: 2843150. DOI: 10.1136/jmg.2008.060152. View